Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Dec 5;8(12):e81234.
doi: 10.1371/journal.pone.0081234. eCollection 2013.

Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research

Affiliations

Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research

Yin Ting Cheung et al. PLoS One. .

Abstract

Objectives: While various clinical and pharmacological determinants for chemotherapy-associated cognitive impairment have been identified, conflicting evidence suggests that cytokines might play an intermediary role. The objective of this systematic review was to evaluate the current evidence pertaining to the associations among chemotherapy, cytokines induction and cognitive impairment in cancer patients.

Methods: A literature search with PubMed and SciVerse Scopus was conducted in March 2013 to gather relevant articles and abstracts that fulfilled the inclusion and exclusion criteria. This review included studies that had performed objective and/or subjective cognitive assessments and cytokine measurements on defined populations of cancer patients who received chemotherapy.

Results: High methodological heterogeneity existed among the selected studies which differed in cancer populations, subject characteristics, cognitive endpoints, types of cytokines tested and their measurement methods. Weak to moderate correlations were observed between IL-1β, IL-6, TNF-α levels, and different degrees of cognitive impairment. Different types of chemotherapy treatments might lead to varying presentations and severities of cytokine-induced cognitive impairment. Notably, the time concordance between the onset of cytokine induction and occurrence of cognitive impairment was not well elucidated. A number of confounding factors was identified to interfere with the expression levels of cytokines; these confounders included subjects' cancer types, ages, genders, genetics and psychosocial characteristics such as anxiety, depression and fatigue.

Conclusion: Although existing studies observed cognitive impairment and cytokine dysregulation in patients who receive chemotherapy, our results suggest that the intermediary role of cytokines in post-chemotherapy cognitive impairment is still controversial and requires further evaluation. A list of methodological recommendations is proposed to harmonize future studies of this subject matter.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Role of cytokines and other determinants in chemotherapy-induced cognitive impairment.
Multiple factors have been postulated as determinants of cognitive changes in cancer patients, including demographical, physiological, psychological, pathological and pharmacological determinants. Recent experimental studies have suggested that pro-inflammatory cytokines may be mediators of chemotherapy-associated cognitive changes.
Figure 2
Figure 2. Results of Literature Search.

Similar articles

Cited by

References

    1. Jim HSL, Phillips KM, Chait S, Faul LA, Popa MA, et al. (2012) Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol 30: 3578–3587. - PMC - PubMed
    1. Cheung YT, Maung Shwe HG, Tan YP, Fan GKT, Ng RCH, et al. (2012) Cognitive changes in multiethnic Asian breast cancer patients: A focus group study. Ann Oncol 23: 2547–2552. - PubMed
    1. Vardy J (2009) Cognitive function in breast cancer survivors. Cancer Treat Res 151: 387–419. - PubMed
    1. Cheung YT, Chui WK, Chan A (2011) Neuro-cognitive impairment in breast cancer patients: Pharmacological considerations. Crit Rev Oncol Hematol 83: 99–111. - PubMed
    1. Munir F, Burrows J, Yarker J, Kalawsky K, Bains M (2010) Women's perceptions of chemotherapy-induced cognitive side affects on work ability: A focus group study. J Clin Nurs 19: 1362–1370. - PubMed

Publication types

MeSH terms